Adverse Effects of Ovarian Suppression and Endocrine Therapy in Patients with Breast Neoplasms: Integrative Literature Review
DOI:
https://doi.org/10.32635/2176-9745.RBC.2026v72n4.5680Keywords:
Breast Neoplasms/drug therapy, Antineoplastic Agents, hormonal/adverse effects, Drug-Related Side Effects and Adverse Reactions, Quality of lifeAbstract
Introduction: Breast cancer is the most common neoplasm among women worldwide and represents a major public health issue. Endocrine therapy (ET) and ovarian function suppression (OFS) are fundamental strategies in the treatment of hormone-sensitive tumors; however, they are associated with adverse effects that may impact quality of life and treatment adherence. Objective: To identify the main adverse effects associated with ET and OFS in patients with breast cancer, analyzing their impact on quality of life and treatment adherence. Method: Integrative literature review, structured according to the PRISMA 2020 recommendations, with methodological adaptations. The search was conducted in February 2025 in PubMed, Scopus, and Web of Science using a PICo-based strategy. Observational studies and clinical trials published between 2015 and 2025 were included. Study selection was performed using the Rayyan software, with screening of titles, abstracts, and full-text assessment of eligible articles. Results: The final sample consisted of eight studies. Evidence indicates that ET and OFS are associated with physical, metabolic, sexual, psychological, and oral adverse effects, including hot flashes, fatigue, insomnia, weight gain, sexual dysfunction, and emotional changes. These effects may impair quality of life and reduce treatment adherence, particularly in combined therapies. Conclusion: Adverse effects associated with ET and OFS are multifactorial and clinically relevant and may negatively impact quality of life and treatment continuity.
Downloads
References
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today [Internet]. Lyon: International Agency for Research on Cancer; 2024 [acesso 2026 jun 15]. Disponível em: https://gco.iarc.who.int/today/en/dataviz/pie?mode=cancer&group_populations=1&sexes=2
Instituto Nacional de Câncer. Estimativa 2026: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2025 [acesso 2026 jun 8]. Disponível em: https://ninho.inca.gov.br/jspui/bitstream/123456789/17914/1/Estima2026_completo%20%281%29.pdf
Ministério da Saúde (BR). Protocolo clínico e diretrizes terapêuticas: câncer de mama [Internet]. Brasília, DF: Ministério da Saúde; 2024 [acesso 2025 fev 13]. Disponível em: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2024/RRPCDTCncerdeMama_CP.pdf
Lu YS, Wong A, Kim HJ. Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptor-positive early breast cancer in premenopausal women. Front Oncol. 2021;11:700722. doi: https://www.doi.org/10.3389/fonc.2021.700722 DOI: https://doi.org/10.3389/fonc.2021.700722
Goel S, Sharma R, Hamilton A, et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009;2009(4):CD004562. doi: https://www.doi.org/10.1002/14651858.CD004562.pub4 DOI: https://doi.org/10.1002/14651858.CD004562.pub3
Molinelli C, Jacobs F, Nader-Marta G, et al. Ovarian suppression: early menopause and late effects. Curr Treat Options Oncol. 2024;25(4):523-42. doi: https://www.doi.org/10.1007/s11864-024-01190-8 DOI: https://doi.org/10.1007/s11864-024-01190-8
Mota de Sousa LM, Furtado Firmino C, Alves Marques-Vieira CM, et al. Revisões da literatura científica: tipos, métodos e aplicações em enfermagem. Rev Port Enferm Reabil. 2018;1(1):45-55. doi: https://www.doi.org/10.33194/rper.2018.v1.n1.07.4391 DOI: https://doi.org/10.33194/rper.2018.v1.n1.07.4391
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: https://www.doi.org/10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi: https://www.doi.org/10.1186/s13643-016-0384-4 DOI: https://doi.org/10.1186/s13643-016-0384-4
O'Reilly D, Farooq AR, Nevins Selvadurai P, et al. Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy. Oncologist. 2024;29(10):842-9. doi: https://www.doi.org/10.1093/oncolo/oyae146 DOI: https://doi.org/10.1093/oncolo/oyae146
Ferreira AR, Di Meglio A, Pistilli B, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol. 2019;30(11):1784-95. doi: https://www.doi.org/10.1093/annonc/mdz298 DOI: https://doi.org/10.1093/annonc/mdz298
Kurebayashi J, Toyama T, Sumino S, et al. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study. Breast Cancer. 2017;24(1):161-70. doi: https://www.doi.org/10.1007/s12282-016-0691-6 DOI: https://doi.org/10.1007/s12282-016-0691-6
Julca-Baltazar JJ, Asmat-Abanto AS, Pantoja-Lázaro AR, et al. Tooth loss in breast cancer patients: a comparison between tamoxifen-treated and non-treated patients. Med Oral Patol Oral Cir Bucal. 2024;29(4):e552-8. doi: https://www.doi.org/10.4317/medoral.26528 DOI: https://doi.org/10.4317/medoral.26528
Hong J, Huang J, Shen L, et al. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. BMC Cancer. 2020;20(1):663. doi: https://www.doi.org/10.1186/s12885-020-07156-x DOI: https://doi.org/10.1186/s12885-020-07156-x
Ribi K, Luo W, Walley BA, et al. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020;181(2):347-59. doi: https://www.doi.org/10.1007/s10549-020-05622-5 DOI: https://doi.org/10.1007/s10549-020-05622-5
Jiang J, Xu J, Cai L, et al. Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists. BMC Psychiatry. 2021;21(1):624. doi: https://www.doi.org/10.1186/s12888-021-03611-6 DOI: https://doi.org/10.1186/s12888-021-03611-6
Uhelski AR, Blackford AL, Sheng JY, et al. Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer. J Cancer Surviv. 2024;18(5):1683-96. doi: https://www.doi.org/10.1007/s11764-023-01408-y DOI: https://doi.org/10.1007/s11764-023-01408-y
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
